These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17223910)

  • 41. Sickle cell disease: progress towards combination drug therapy.
    Pace BS; Starlard-Davenport A; Kutlar A
    Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sickle cell disease: What all PAs should know.
    Kayinqo G
    JAAPA; 2012 Sep; 25(9):19-20. PubMed ID: 22991882
    [No Abstract]   [Full Text] [Related]  

  • 43. Sickle cell disease--pathophysiology and treatment.
    Redding-Lallinger R; Knoll C
    Curr Probl Pediatr Adolesc Health Care; 2006; 36(10):346-76. PubMed ID: 17055417
    [No Abstract]   [Full Text] [Related]  

  • 44. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
    Khayat AS; Antunes LM; Guimarães AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
    Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood plasma metabolomics of children and adolescents with sickle cell anaemia treated with hydroxycarbamide: a new tool for uncovering biochemical alterations.
    Ribeiro PR; Teixeira RDS; Souza AR; Pereira TCS; Boffo EF; Carosio MGA; Ferreira AG; Oliveira RV; Rodrigues LEA; Silva JJ; de Souza AJ; Ladeia AMT
    Br J Haematol; 2021 Mar; 192(5):922-931. PubMed ID: 33476407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anaemia.
    Costa FC; da Cunha AF; Fattori A; de Sousa Peres T; Costa GG; Machado TF; de Albuquerque DM; Gambero S; Lanaro C; Saad ST; Costa FF
    Br J Haematol; 2007 Jan; 136(2):333-42. PubMed ID: 17156400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experimental therapy.
    Charache S
    Hematol Oncol Clin North Am; 1996 Dec; 10(6):1373-82. PubMed ID: 8956024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease.
    Bakshi N; Sinha CB; Ross D; Khemani K; Loewenstein G; Krishnamurti L
    PLoS One; 2017; 12(7):e0178413. PubMed ID: 28727801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
    Puffer E; Schatz J; Roberts CW
    Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S; Haywood C; Segal JB; Dover GJ
    Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 54. Bone marrow transplantation (BMT) and gene replacement therapy (GRT) in sickle cell anemia.
    Misaki W
    Niger J Med; 2008; 17(3):251-6. PubMed ID: 18788247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sickle cell disease.
    McCavit TL
    Pediatr Rev; 2012 May; 33(5):195-204; quiz 205-6. PubMed ID: 22550263
    [No Abstract]   [Full Text] [Related]  

  • 56. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease.
    Mahadeo KM; Oyeku S; Taragin B; Rajpathak SN; Moody K; Santizo R; Driscoll MC
    Am J Hematol; 2011 Sep; 86(9):806-8. PubMed ID: 21850660
    [No Abstract]   [Full Text] [Related]  

  • 57. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.
    Amrolia PJ; Almeida A; Halsey C; Roberts IA; Davies SC
    Br J Haematol; 2003 Mar; 120(5):725-36. PubMed ID: 12614202
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.
    Walters MC; Storb R; Patience M; Leisenring W; Taylor T; Sanders JE; Buchanan GE; Rogers ZR; Dinndorf P; Davies SC; Roberts IA; Dickerhoff R; Yeager AM; Hsu L; Kurtzberg J; Ohene-Frempong K; Bunin N; Bernaudin F; Wong WY; Scott JP; Margolis D; Vichinsky E; Wall DA; Wayne AS; Pegelow C; Redding-Lallinger R; Wiley J; Klemperer M; Mentzer WC; Smith FO; Sullivan KM
    Blood; 2000 Mar; 95(6):1918-24. PubMed ID: 10706855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.
    Amrolia PJ; Almeida A; Davies SC; Roberts IA
    Br J Haematol; 2003 Mar; 120(5):737-43. PubMed ID: 12614203
    [No Abstract]   [Full Text] [Related]  

  • 60. The effect of sickle cell anemia on the linear growth of Nigerian children.
    Chikani UN; Bisi-Onyemaechi A; Ohuche I; Onu J; Ugege S; Ogugua C; Mbanefo N; Chime P; Emodi I
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1283-1290. PubMed ID: 34271599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.